[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nsclc-recurrent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nsclc-recurrent":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,77,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":48,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100520064","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mesothelin-targeting-logic-gated-car-t-in-participants-with-solid-tumors-that-express-msln-and-have-lost-hla-a02-expression-100520064",false,"NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion","ALL","18 Years",{"count":20,"type":21},474,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"Solid Tumor, Adult","Colorectal Cancer","NSCLC","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreas Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Colon Cancer","Rectal Cancer","Cancer","Ovarian Cancer","Ovarian Neoplasms","Mesothelioma","Mesothelioma, Malignant","Ovary Cancer","Lung Cancer","MESOM",[49,50,51,52,53,54,55,56,57,58,59,60,40,61,37,29,46,30,62,47,41,43,63],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Pancreatic","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate","RECRUITING","2026-06-10",{"date":67,"type":68},"2026-06-12","ACTUAL",{"date":70,"type":68},"2024-04-03",{"date":72,"type":21},"2029-06",{"name":74,"class":75},"A2 Biotherapeutics Inc.","INDUSTRY",12,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100398406","phase-1-combination-of-atezolizumab-and-pirfenidone-in-second-line-and-beyond-nsclc-100398406","NCT04467723","Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC","CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I\u002FII Study","Inclusion Criteria:\n\n* Participant or legal representative is able to provide written informed prior to performing any protocol-related procedures\n* Is willing and able to comply with scheduled visits, treatment schedule, laboratory testing and other requirements of the study\n* Men or women at least 18 years of age with histologically or cytologically confirmed non-small cell lung cancer\n* Previous history of other than lung cancer is allowed if no active treatment for that cancer within 1 year\n* Life expectancy of at least 6 months\n* De novo stage IV or recurrent NSCLC without actionable mutation (e.g. EGFR\u002F ALK\u002F ROS-1) that was previously treated with either PD-1 \u002F PD-L1 or the combination of PD1\u002FPDL1 and cytotoxic chemotherapy, no more than 2 systemic regimens for metastatic disease with measurable disease \\*. Maintenance therapy will be considered part of the 1 regimen\n* At least 1 measurable lesion\n* PDL1 TPS score less than 1% or unknown: first-line must be PD1\u002FPDL1 inhibitor in combination with chemotherapy\n* Early stage (I-III) NSCLC treated with adjuvant or neoadjuvant chemotherapy then PD1\u002FPDL1 inhibitor treatment for recurrent disease\n* Recurrent Unresectable stage III NSCLC treated with prior chemoradiation followed by maintenance PD1\u002FPDL1 inhibitor with measurable disease\n* Eastern Cooperative Group (ECOG) Performance Status 0 - 2\n* Is able to swallow oral medications\n* Adequate hematologic function\n* Adequate organ function\n\nExclusion Criteria:\n\n* The presence of any other concurrent severe and\u002For uncontrolled medical condition that would, in the investigator or treating physician's judgement, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol\n* Has received investigational agents within 14 days or 5 half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment\n* Has a known hypersensitivity to atezolizumab or pirfenidone\n* Has active medical or psychiatric illness that would interfere with the study treatment\n* Has uncontrolled diabetes\n* Has any of the following cardiac diagnoses:\n\nUnstable angina Myocardial infarction within 6 months Uncontrolled congestive heart failure Left ventricular ejection fraction \\\u003C 35%\n\n* Has a history of any Grade 3 or 4 toxicities to a prior checkpoint inhibitor treatment\n* Is pregnant or breast feeding\n* Uncontrolled HIV\n* Clinically diagnosed with grade 2 or 3 radiation-induced lung injury within the last 3 months prior to registering for the study\n* Has a history of idiopathic pneumonitis that required systemic agent including steroid\n* Has drug-induced pneumonitis\n* Has evidence of active pneumonitis on screening chest computed tomography (CT) scan\n* Smoker of more than 1 pack \u002F day\n* Has active peptic ulcer diagnosed within 4 weeks of enrollment\n* Active infection requiring systemic treatment\n* Current use of systemic antibacterial or antifungal agent\n* Prior monoclonal antibody within 4 weeks before study Day 1 Exception: The use of denosumab\n* Patient not recovered to ≤ Grade 1 from AEs due to agents administered more than 4 weeks earlier\n* Concurrent use of other investigational agents\n* Uncontrolled or symptomatic brain metastasis or leptomeningeal disease that requires use of steroids\n* Use of strong CYP1A2 inhibitors\n* Previous history of cancer with active treatment within less than 1 year of enrollment\n* Active auto-immune diseases",{"count":85,"type":21},25,[24,25],"The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.",[89,32],"NSCLC Stage IV","2026-01-26",{"date":92,"type":68},"2026-01-28",{"date":94,"type":68},"2022-05-18",{"date":96,"type":21},"2027-08",{"name":98,"class":99},"University of Kansas Medical Center","OTHER",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":100},"100493179","molecular-landscape-analysis-and-clinical-implications-for-nsclc-patients-with-rare-mutations-100493179","NCT05701787","Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","Molecular Landscape Analysis and Clinical and Therapeutic Implications for NSCLC Patients With Rare Mutations","Inclusion Criteria:\n\n* Histologically proven diagnosis of NSCLC with rare mutations including EGFR rare mutations, ALK fusion, ROS1 fusion, BRAF V600E, cMET exon 14 skipping, KRAS G12C, RET fusion, NTRK fusion, etc.\n* 18 years of age or older\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* None",{"count":109,"type":21},500,"OBSERVATIONAL","Lung cancer is the most common primary cancer of the lung and is responsible for the ever increasing number of cancer-related deaths worldwide. Especially in China, the burden of lung cancer has been rising rapidly due to its large and growing population. Histologically, approximately 85% of lung cancers are non-small-cell lung cancer (NSCLC).\n\nMolecular targeted therapy has been shown to dramatically improve the quality of life and survival outcomes of NSCLC patients. One of the most important targeted drugs in NSCLC has been the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), while there exists some other rare targetable mutation in NSCLC. Emerging evidence underlines that, rather than a single point mutation, some rare mutations present with a wide array of mutations, essentially in NSCLC.\n\nDifferent rare mutations with NSCLC have divergent clinical and therapeutic implications with a particular distinction. Therefore, there is an unmet need for more effective therapies for NSCLC with rare mutations. In summary, identification of genetic alterations in NSCLC with rare mutations is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with NSCLC with rare mutations to further the characterization of molecular alterations and develop (novel) treatments based on the detection.",[30,89,32],[30,114,115,116,117,118,119],"rare mutations","molecular landscape","next-generation sequencing (NGS)","targeted therapy","immunotherapy","chemotherapy","2025-05-20",{"date":122,"type":68},"2025-05-22",{"date":124,"type":68},"2019-01-01",{"date":126,"type":21},"2029-12-31",{"name":128,"class":99},"Shanghai Chest Hospital"]